{
  "id": "5c6e0f537c78d6947100004a",
  "type": "factoid",
  "question": "Which molecule is inhibited by larotrectinib?",
  "ideal_answer": "Larotrectinib is oral, potent, and selective inhibitor of tropomyosin receptor kinases (TRK). It demonstrated unprecedented efficacy on unresectable or metastatic solid tumors with neurotrophic tropomyosin receptor kinase (NTRK)-fusion proteins in adult and pediatric patients.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/30069765",
    "http://www.ncbi.nlm.nih.gov/pubmed/29466156",
    "http://www.ncbi.nlm.nih.gov/pubmed/29568395",
    "http://www.ncbi.nlm.nih.gov/pubmed/29653952",
    "http://www.ncbi.nlm.nih.gov/pubmed/30204247",
    "http://www.ncbi.nlm.nih.gov/pubmed/28578312",
    "http://www.ncbi.nlm.nih.gov/pubmed/30350734",
    "http://www.ncbi.nlm.nih.gov/pubmed/29606586",
    "http://www.ncbi.nlm.nih.gov/pubmed/29764494"
  ],
  "snippets": [
    {
      "text": "We evaluated the efficacy and safety of larotrectinib, a highly selective TRK inhibitor, in adults and children who had tumors with these fusions.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29466156",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: Larotrectinib had marked and durable antitumor activity in patients with TRK fusion-positive cancer, regardless of the age of the patient or of the tumor type.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29466156",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Larotrectinib, a highly selective small-molecule inhibitor of the TRK kinases, had shown activity in preclinical models and in adults with tumours harbouring TRK fusions.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29606586",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTERPRETATION: The TRK inhibitor larotrectinib was well tolerated in paediatric patients and showed encouraging antitumour activity in all patients with TRK fusion-positive tumours.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29606586",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In the 2017 American Society for Clinical Oncology annual meeting, larotrectinib (LOXO-101), Loxooncology's oral, potent, and selective inhibitor of tropomyosin receptor kinases (TRK), demonstrated unprecedented efficacy on unresectable or metastatic solid tumors with neurotrophic tropomyosin receptor kinase (NTRK)-fusion proteins in adult and pediatric patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29764494",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Larotrectinib Has Antitumor Activity in TRK",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29653952",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Larotrectinib achieved a 93% response rate in pediatric patients with TRK fusion-positive tumors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29653952",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "To recapitulate resistance observed from type I NTRK kinase inhibitors entrectinib and larotrectinib, we generated NIH-3T3 cells exogenously expressing TPM3-NTRK1 wild-type, or acquired mutations G595R and G667C in vitro and in vivo.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29568395",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Larotrectinib is the first highly potent and selective small molecule ATP competitive inhibitor of all three TRK kinases to enter clinical development. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30350734",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Larotrectinib is the first highly potent and selective small molecule ATP competitive inhibitor of all three TRK kinases to enter clinical development.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30350734",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Areas covered: This review covers the current preclinical and clinical evidence for TRK inhibitors for TRK fusion cancers, focusing on larotrectinib.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30350734",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Larotrectinib, a highly selective small-molecule inhibitor of the TRK kinases, had shown activity in preclinical models and in adults with tumours harbouring TRK fusions.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29606586",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND\nThe highly selective oral tropomyosin receptor kinase (TRK) inhibitor larotrectinib has demonstrated significant activity in adult and pediatric TRK fusion cancers.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30204247",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTERPRETATION\nThe TRK inhibitor larotrectinib was well tolerated in paediatric patients and showed encouraging antitumour activity in all patients with TRK fusion-positive tumours.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29606586",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Several TRK inhibitors have been developed, and one of them, Larotrectinib (formerly known as LOXO-101), represents an orally available, selective inhibitor of the TRK receptor family that has already shown substantial clinical benefit in both pediatric and adult patients harboring an NTRK gene fusion over the last few years.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30069765",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND The highly selective oral tropomyosin receptor kinase (TRK) inhibitor larotrectinib has demonstrated significant activity in adult and pediatric TRK fusion cancers.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30204247",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Larotrectinib, a selective TRK tyrosine kinase inhibitor (TKI), has demonstrated histology-agnostic efficacy in patients with TRK fusion-positive cancers.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28578312",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Areas covered: This review covers the current preclinical and clinical evidence for TRK inhibitors for TRK fusion cancers, focusing on larotrectinib.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30350734",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Several TRK inhibitors have been developed, and one of them, Larotrectinib (formerly known as LOXO-101), represents an orally available, selective inhibitor of the TRK receptor family that has already shown substantial clinical benefit in both pediatric and adult patients harboring an NTRK gene fusion over the last few years.<br>",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30069765",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "tropomyosin receptor kinases"
}